The National Institutes of Health (NIH) has granted $718,136 in funding to the University of California San Francisco (UCSF) to discover and optimise oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals.

Anacor has partnered with UCSF to develop new antimalarial agents.

In addition Anacor works with Medicines for Malaria Venture (MMV) to develop AN3661, a boron-based antimalarial compound currently in preclinical trials.

Anacor and MMV plan to conduct Phase 1 and Phase 2 proof of concept studies for AN3661, where GSK will have the option to license the programme.